Diagnosis and treatment of bladder cancer: How can we improve?

Postgraduate Medicine

Volumn 124, Issue 3, 2012, Pages 28-36

  Gorin, Michael A ^a   Ayyathurai, Rajinikanth ^b   Soloway, Mark S ^b  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Bacille calmette gu rin; BCG; Bladder cancer; Cystoscopy; Intravesicle chemotherapy; Transurethral resection; TURBT; Urothelial carcinoma

Indexed keywords

BCG VACCINE; CISPLATIN; DOXORUBICIN; GEMCITABINE; METHOTREXATE; PACLITAXEL; VINBLASTINE; ANTINEOPLASTIC AGENT;

ARTICLE; BLADDER CANCER; BLADDER TUMOR; CANCER GRADING; CANCER PROGNOSIS; CANCER SCREENING; CANCER STAGING; CYSTOSCOPY; DELAYED DIAGNOSIS; DIAGNOSTIC ACCURACY; FLEXIBLE CYSTOSCOPY; HEMATURIA; HISTORY; HUMAN; METASTASIS; PHYSICAL EXAMINATION; TRANSITIONAL CELL CARCINOMA; TRANSURETHRAL RESECTION; UNSPECIFIED SIDE EFFECT; URINARY TRACT; URINE CYTOLOGY; UROGRAPHY; ANAMNESIS; CANCER INVASION; CYSTECTOMY; CYTOLOGY; DIAGNOSTIC IMAGING; MASS SCREENING; MULTIMODALITY CANCER THERAPY; REVIEW; URINE; UROLOGIC SURGERY;

ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; CYSTECTOMY; CYSTOSCOPY; DIAGNOSTIC IMAGING; HUMANS; MASS SCREENING; MEDICAL HISTORY TAKING; NEOPLASM GRADING; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PHYSICAL EXAMINATION; URINARY BLADDER NEOPLASMS; URINE; UROLOGIC SURGICAL PROCEDURES;

EID: 84867867532     PISSN: 00325481     EISSN: 19419260     Source Type: Journal    
DOI: 10.3810/pgm.2012.05.2545     Document Type: Article

References (53)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69-90.
2. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62(1):10-29.
3. Lynch CF, Cohen MB. Urinary system. Cancer. 1995;75(1 suppl): 316-329.
4. Grossfeld GD, Wolf JS, Jr, Litwin MS, et al. Asymptomatic microscopic hematuria in adults: summary of the AUA best practice policy recommendations. Am Fam Physician. 2001;63(6):1145-1154.
5. Strope SA, Montie JE. The causal role of cigarette smoking in bladder cancer initiation and progression, and the role of urologists in smoking cessation. J Urol. 2008;180(1):31-37.
6. Hirao Y, Kim WJ, Fujimoto K. Environmental factors promoting bladder cancer. Curr Opin Urol. 2009;19(5):494-499.
7. Volanis D, Kadiyska T, Galanis A, Delakas D, Logotheti S, Zoumpourlis V. Environmental factors and genetic susceptibility promote urinary bladder cancer. Toxicol Lett. 2010;193(2):131-137.
8. Lee CT, Madii R, Daignault S, et al. Cystectomy delay more than 3 months from initial bladder cancer diagnosis results in decreased disease specific and overall survival. J Urol. 2006;175(4): 1262-1267.
9. Hollenbeck BK, Dunn RL, Ye Z, et al. Delays in diagnosis and bladder cancer mortality. Cancer. 2010;116(22):5235-5242.
10. Nieder AM, Lotan Y, Nuss GR, et al. Are patients with hematuria appropriately referred to Urology? A multi-institutional questionnaire based survey. Urol Oncol. 2010;28(5):500-503.
11. Soloway MS. Flexible cystourethroscopy: alternative to rigid instruments for evaluation of lower urinary tract. Urology. 1985;25(5): 472-474.
12. Young MJ, Soloway MS. Office evaluation and management of bladder neoplasms. Urol Clin North Am. 1998;25(4):603-611.
13. Sylvester RJ, van der Meijden AP, Oosterlinck W, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol. 2006;49(3):466-475.
14. Hall MC, Chang SS, Dalbagni G, et al. Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update. J Urol. 2007;178(6):2314-2330.
15. Babjuk M, Oosterlinck W, Sylvester R, et al; European Association of Urology (EAU). EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update. Eur Urol. 2011;59(6): 997-1008.
16. National Comprehensive Cancer Network. National Comprehensive Cancer Network (NCCN) 2011 Guidelines on Bladder Cancer. http://www.nccn.org. Accessed March 5, 2012.
17. Sylvester RJ, Oosterlinck W, van der Meijden AP. A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials. J Urol. 2004;171(6 pt 1): 2186-2190.
18. Montironi R, Lopez-Beltran A. The 2004 WHO classification of bladder tumors: a summary and commentary. Int J Surg Pathol. 2005; 13(2):143-153.
19. Edge SB, Byrd DR, Compton CC, Fritz AG, eds. American Joint Committee on Cancer: AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer; 2009.
20. Mungan NA, Kiemeney LA, van Dijck JA, van der Poel HG, Witjes JA. Gender differences in stage distribution of bladder cancer. Urology. 2000;55(3):368-371.
21. Soloway MS, Bruck DS, Kim SS. Expectant management of small, recurrent, noninvasive papillary bladder tumors. J Urol. 2003;170(2 pt 1): 438-441.
22. Sylvester RJ, van der Meijden AP, Witjes JA, Kurth K. Bacillus calmette-guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials. J Urol. 2005;174(1): 86-91.
23. Malmstrom PU, Sylvester RJ, Crawford DE, et al. An individual patient data meta-analysis of the long-term outcome of randomized studies comparing intravesical mitomycin C versus bacillus Calmette-Guerin for non-muscle-invasive bladder cancer. Eur Urol. 2009;56(2): 247-256.
24. Shelley MD, Mason MD, Kynaston H. Intravesical therapy for superficial bladder cancer: a systematic review of randomized trials and meta-analyses. Cancer Treat Rev. 2010;36(3):195-205.
25. Koya MP, Simon MA, Soloway MS. Complications of intravesical therapy for urothelial cancer of the bladder. J Urol. 2006;175(6): 2004-2010.
26. Nieder AM, Simon MA, Kim SS, Manoharan M, Soloway MS. Radical cystectomy after bacillus Calmette-Guerin for high-risk Ta, T1, and carcinoma in situ: defining the risk of initial bladder preservation. Urology. 2006;67(4):737-741.
27. Advanced Bladder Cancer Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and metaanalysis. Lancet. 2003;361(9373):1927-1934.
28. Porter MP, Kerrigan MC, Donato BM, Ramsey SD. Patterns of use of systemic chemotherapy for Medicare beneficiaries with urothelial bladder cancer. Urol Oncol. 2011;29(3):252-258.
29. Calabro F, Sternberg CN. Neoadjuvant and adjuvant chemotherapy in muscle-invasive bladder cancer. Eur Urol. 2009;55(2):348-358.
30. Hautmann RE. Urinary diversion: ileal conduit to neobladder. J Urol. 2003;169(3):834-842.
31. Zapatero A, Martin de Vidales C, Arellano R, Bocardo G, Perez M, Rios P. Updated results of bladder-sparing trimodality approach for invasive bladder cancer. Urol Oncol. 2010;28(4):368-374.
32. Maarouf AM, Khalil S, Salem EA, ElAdl M, Nawar N, Zaiton F Bladder preservation multimodality therapy as an alternative to radical cystectomy for treatment of muscle invasive bladder cancer. BJU Int. 2011; 107(10):1605-1610.
33. Babaian RJ, Johnson DE, Llamas L, Ayala AG. Metastases from transitional cell carcinoma of urinary bladder. Urology. 1980;16(2): 142-144.
34. von der Maase H, Hansen SW, Roberts JT, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol. 2000;18(17): 3068-3077.
35. von der Maase H, Sengelov L, Roberts JT, et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol. 2005;23(21):4602-4608.
36. Bellmunt J, von der Maase H, Mead GM, et al. Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy. J Clin Oncol. 2007; 25(18s):965.
37. Guzzo TJ, Hockenberry MS, Mucksavage P, Bivalacqua TJ, Schoenberg MP. Smoking knowledge assessment and cessation trends in patients with bladder cancer presenting to a tertiary referral center. Urology. 2012;79(1):166-171.
38. Youakim S. Risk of cancer among firefighters: a quantitative review of selected malignancies. Arch Environ Occup Health. 2006;61(5): 223-231.
39. Reulen RC, Kellen E, Buntinx F, Brinkman M, Zeegers MP. A metaanalysis on the association between bladder cancer and occupation. Scand J Urol Nephrol Suppl. 2008;(218):64-78.
40. Colt JS, Karagas MR, Schwenn M, et al. Occupation and bladder cancer in a population-based case-control study in Northern New England. Occup Environ Med. 2011;68(4):239-249.
41. Britton JP, Dowell AC, Whelan P, Harris CM. A community study of bladder cancer screening by the detection of occult urinary bleeding. J Urol. 1992;148(3):788-790.
42. Lokeshwar VB, Habuchi T, Grossman HB, et al. Bladder tumor markers beyond cytology: International Consensus Panel on bladder tumor markers. Urology. 2005;66(6 suppl 1):35-63.
43. Chou R, Dana T. Screening adults for bladder cancer: a review of the evidence for the U.S. preventive services task force. Ann Intern Med. 2010;153(7):461-468.
44. Moyer VA; U.S. Preventive Services Task Force. Screening for bladder cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2011;155(4):246-251.
45. Soloway MS. Bladder carcinoma: where are the patient advocates? Cancer. 2005;104(8):1559-1562.
46. Stenzl A, Burger M, Fradet Y, et al. Hexaminolevulinate guided fluorescence cystoscopy reduces recurrence in patients with nonmuscle invasive bladder cancer. J Urol. 2010;184(5):1907-1913.
47. Isfoss BL. The sensitivity of fluorescent-light cystoscopy for the detection of carcinoma in situ (CIS) of the bladder: a metaanalysis with comments on gold standard. BJU Int. 2011;108(11): 1703-1707.
48. Cauberg EC, Mamoulakis C, de la Rosette JJ, de Reijke TM. Narrow band imaging-assisted transurethral resection for non-muscle invasive bladder cancer significantly reduces residual tumour rate. World J Urol. 2011;29(4):503-509.
49. Herr HW, Donat SM. Reduced bladder tumour recurrence rate associated with narrow-band imaging surveillance cystoscopy. BJU Int. 2011;107(3):396-398.
50. Luciani LG, Neulander E, Murphy WM, Wajsman Z. Risk of continued intravesical therapy and delayed cystectomy in BCG-refractory superficial bladder cancer: an investigational approach. Urology. 2001; 58(3):376-379.
51. Soloway MS, Hepps D, Katkoori D, Ayyathurai R, Manoharan M. Radical cystectomy for BCG failure: has the timing improved in recent years? BJU Int. 2011;108(2):182-185.
52. SEER. SEER Cancer Statistics Review 1975-2008. http://seer.cancer. gov/csr/19752008/. Accessed March 5, 2012.
53. Bladder Cancer Advocacy Network. Bladder cancer basics for the newly diagnosed. http://bcan.org. Accessed March 5, 2012.